
Novo Nordisk hits back at copycat drugs
FT News Briefing
00:00
Why Novo is under pressure
Patrick outlines Novo's sales decline, competition from Eli Lilly, pricing deals and recent trial setbacks.
Play episode from 03:58
Transcript

Patrick outlines Novo's sales decline, competition from Eli Lilly, pricing deals and recent trial setbacks.